<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01763385</url>
  </required_header>
  <id_info>
    <org_study_id>2012-75-634</org_study_id>
    <nct_id>NCT01763385</nct_id>
  </id_info>
  <brief_title>Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases</brief_title>
  <acronym>TRACTS</acronym>
  <official_title>Erlotinib With Concurrent Brain Radiotherapy and Secondary Brain Radiotherapy After Recurrence With Erlotinib in NSCLC Non-increased-intracranial-pressure Symptomatic Brain Metastases: A Prospective Multicenter Trial(TRACTS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wu Jieping Medical Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Longhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Armed Police Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Chest Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wu Jieping Medical Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is aim to explore non-increased-intracranial-pressure symptomatic brain&#xD;
      metastases of NSCLC, and if the OS of secondary brain radiotherapy after recurrence with&#xD;
      Erlotinib is better than Erlotinib with concurrent brain radiotherapy. Treatment group are&#xD;
      treated with Erlotinib until brain tumor progression, then gave brain radiotherapy, and&#xD;
      continued to take Erlotinib till extracranial lesions progression. Control group are&#xD;
      Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after&#xD;
      radiotherapy until recurrence or termination for other reasons.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>3.5year</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Non-small-cell Lung Cancer</condition>
  <condition>Brain Metastases</condition>
  <arm_group>
    <arm_group_label>Erlotinib &amp; secondary brain radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Erlotinib until brain tumor progression, then given brain radiotherapy, and continued to take Erlotinib till extracranial lesions progression.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erlotinib &amp; concurrent brain radiotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Erlotinib with concurrent brain radiotherapy, and continued to take Erlotinib after radiotherapy until recurrence or termination for other reasons</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <arm_group_label>Erlotinib &amp; concurrent brain radiotherapy</arm_group_label>
    <arm_group_label>Erlotinib &amp; secondary brain radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>concurrent brain radiotherapy</intervention_name>
    <arm_group_label>Erlotinib &amp; concurrent brain radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>secondary brain radiotherapy</intervention_name>
    <arm_group_label>Erlotinib &amp; secondary brain radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Over the age of 18 years old;&#xD;
&#xD;
          2. Tissue or cell pathological diagnosis of NSCLC;&#xD;
&#xD;
          3. Brain CT or MR validated BM;&#xD;
&#xD;
          4. Non-increased-intracranial-pressure symptomatic BM;&#xD;
&#xD;
          5. Haven't received TKI target treatment;&#xD;
&#xD;
          6. Haven't received brain radiotherapy;&#xD;
&#xD;
          7. Patients in initial treatment should be detected EGFR mutation;&#xD;
&#xD;
          8. Expected survival more than 6 months;&#xD;
&#xD;
          9. KPS no less than 70, or KPS less than 70 caused by paralysis due to recent brain&#xD;
             metastases;&#xD;
&#xD;
         10. Liver and kidney function requirements: SGOT/SGPT≦2.5 times of the upper limit, Total&#xD;
             bilirubin≦1.5 times of the upper limit, serum Creatinine≦1.5 times of the upper limit;&#xD;
&#xD;
         11. Routine blood test requirements: WBC≧3.0×109/L, NE≧1.8×109/L, PLT≧90×109/L，no&#xD;
             requirement for Hb;&#xD;
&#xD;
         12. Blood glucose requirements: within the normal range, diabetic patients are receiving&#xD;
             treatment and their glucose was being controlled in a steady state;&#xD;
&#xD;
         13. Female patients in childbearing age: HCG (-);&#xD;
&#xD;
         14. Patients signed an inform Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Those with Erlotinib drug allergies;&#xD;
&#xD;
          2. Those with mathematical understanding of the most simple life questions, such as&#xD;
             &quot;walking&quot;, those difficult for doctors to communicate;&#xD;
&#xD;
          3. Those without guardians or families;&#xD;
&#xD;
          4. Those with abnormal routine blood test, liver and kidney function, and blood glucose&#xD;
             beyond the above boundaries and difficult to correcting for more than 2 weeks;&#xD;
&#xD;
          5. Those with any unstable medical status (including active infection, uncontrolled&#xD;
             hypertension, unstable angina, congestive heart failure, myocardial infarction (within&#xD;
             one year before treatment initiation), and severe arrhythmia, liver, kidney or&#xD;
             metabolic disease requiring drug therapy);&#xD;
&#xD;
          6. Those with any other disease, neurological or metabolic dysfunction, and physical&#xD;
             examination or laboratory test results showed that the study drugs may increase the&#xD;
             risk of treatment-related complications;&#xD;
&#xD;
          7. Pregnant women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huanjun Yang</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huanjun Yang, Master</last_name>
    <phone>+86-21-64175590</phone>
    <phone_ext>6723</phone_ext>
    <email>yanghj_1@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huanjun Yang, Master</last_name>
      <phone>+86-21-64175590</phone>
      <phone_ext>6723</phone_ext>
      <email>yanghj_1@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>January 4, 2013</study_first_submitted>
  <study_first_submitted_qc>January 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2013</study_first_posted>
  <last_update_submitted>December 22, 2014</last_update_submitted>
  <last_update_submitted_qc>December 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Yang Huan Jun</investigator_full_name>
    <investigator_title>Fudan University</investigator_title>
  </responsible_party>
  <keyword>Erlotinib</keyword>
  <keyword>brain radiotherapy</keyword>
  <keyword>NSCLC</keyword>
  <keyword>brain metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

